Shares of XOMA Corp (NASDAQ:XOMA) have received an average rating of “Hold” from the ten analysts that are presently covering the company, American Banking News.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $9.00. XOMA Corp (NASDAQ:XOMA) shares advanced 5.04% in last trading session and ended the day on $5.21. XOMA its return on assets is -152.10%. XOMA Corp (NASDAQ:XOMA) yearly performance is 51.01%.
Cohen Milstein Sellers & Toll PLLC on Mar. 28 said it is conducting an investigation to determine whether Galena Biopharma Inc (NASDAQ:GALE) and certain of its officers and directors made false and misleading statements and/or omissions in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. A class action lawsuit was filed in the U.S. District Court for the District of Oregon by another law firm on behalf of purchasers of the common stock of Galena Biopharma, Inc. (GALE) between November 6, 2013 and February 14, 2014, inclusive (the “Class Period”). Galena Biopharma Inc (NASDAQ:GALE) shares moved up 12.61% in last trading session and was closed at $2.50, while trading in range of $2.18-$2.50. Galena Biopharma Inc (NASDAQ:GALE) year to date performance is -49.60%.
Alnylam Pharmaceuticals (NASDAQ:ALNY) major shareholder Sanofi purchased 344,448 shares of the stock on the open market in a transaction that occurred on Tuesday, March 25th. The stock was purchased at an average cost of $66.88 per share, for a total transaction of $23,036,682.24. The transaction was disclosed in a document filed with the SEC. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) weekly performance is 1.59%. On last trading day company shares ended up $67.14. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) distance from 50-day simple moving average is -14.86%. Analysts mean target price for the company is $101.00.